Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Bullboard Posts
Comment by lv_426on Nov 23, 2019 6:57pm
56 Views
Post# 30386049

RE:RE:RE:$1.00 - $4.00 Share Price in 6-12 months

RE:RE:RE:$1.00 - $4.00 Share Price in 6-12 months
Inv3strr wrote:

@lv_426.   -- Of course there are ifs because we have to use the information we know.  If we were making choices without "ifs" we wouldn't have to speculate.  So investing in a pre revenue company is entirely about making educated decisions and that means we have to assume some things.  It's a risk we take. No such thing as certainty. 

the market dictates the price but IF certain things happen it will go up and the "if events" that might happen are based on information that tells me that it's more likely than not ... sometimes less likely.  It's always speculation but if I knew everything I'd not have to do all this research. Also I'd be warren buffet  


so here's my challenge to you.. give me a detailed and reasoned answer about what you think about the likelihood that the injector will launch in 2020 and what that will do to the share price.  Forget the rest for now.  And obviously we don't have proof. But if we had proof the price would be higher already and then we'd not get to make money because we buy after the share price is already up 



What I know is that replicel is out of money. There ability to raise cash is over. Based on that, even if you believe replicel about getting the CE, how will they market without cash? What is business model? Are the injectors sold at cost, so the profit is in the disposable parts? Do they give so many away to drive adoption(this costs money they have)? How quick is mass adoption? Highly doubts it's over night....months,years? Honestly if I want to dream I'll but a lottery ticket
Bullboard Posts